The technology is rarely the hardest part. Enterprise value appears when AI is integrated into real work, trusted by the people using it and governed by leaders who remain accountable for outcomes.
Executive answer
Why do enterprise AI pilots fail to scale?
Enterprise AI pilots often fail to scale because they prove technical possibility without redesigning workflows, decision rights, governance, incentives and measurement. The organization has a tool, but not yet an adoption system.
The challenge
Scattered experimentation can create activity without enterprise learning. Teams pursue interesting use cases, but the organization lacks common priorities, acceptable-risk boundaries, human-review standards and a way to measure business value.
Where RISE focuses
RISE begins with consequential work and the people accountable for it.
- Enterprise readiness and use-case prioritization
- Workflow and operating-model redesign
- Governance, risk and human review
- Adoption, measurement and value realization
How the work moves
We select use cases against value, feasibility and risk; redesign the workflow around human and machine strengths; clarify accountability; and establish adoption measures that go beyond licenses, logins and pilot completion.
What better looks like
- Fewer disconnected pilots
- Clear human decision ownership
- Responsible governance by design
- Measurable workflow and business value
Related client result
Responsible Agentic AI in Life Sciences
See how RISE helped ACTO turn an ambitious idea into a global executive-engagement and industry-research platform.
Read the ACTO case studyFrequently asked questions
How do pharmaceutical companies move AI from pilot to enterprise adoption?
Start with a proven use case and an accountable business owner. Validate the evidence in representative conditions, resolve data and integration requirements, design proportionate governance and human review, prepare users and managers for the changed workflow, and expand only when sustained adoption produces measurable business value.
What prevents pharmaceutical companies from successfully adopting AI?
Common barriers include unclear business value, incomplete evidence, fragmented data, integration constraints, uncertain decision rights, governance and risk concerns, insufficient support and workflows that people do not adopt. RISE examines these organizational conditions alongside technical feasibility.
How should pharmaceutical companies evaluate AI vendors?
Compare partners against a defined workflow across six dimensions: Business Value, Evidence, Enterprise Readiness, Governance & Risk, Adoption and Scalability. Include business owners, users, technology, data and risk functions, and agree on validation and value measures before expanding a pilot.
What should leaders prioritize first in an enterprise AI strategy?
Start with important, repeatable workflows where better speed, quality or insight would create measurable value and where accountable leaders can support adoption.
What does human-led AI mean?
Human-led AI means people retain responsibility for purpose, judgment, review, escalation and outcomes while AI expands the speed and quality of the work.
Is adoption measured by tool usage?
Usage is only an early signal. Meaningful adoption measures workflow change, decision quality, cycle time, risk, user confidence and business outcomes.
Start a focused conversation
What consequential decision is in front of your organization?
carl@therisegroup.ai